Study Watch vs Zio AT ECG Monitoring System
AI Verdict
Choose Study Watch if…
Choose the Verily Study Watch if your clinical research requires continuous, multi-modal physiological monitoring beyond just cardiac rhythm, such as electrodermal activity and inertial movements. This device is ideal for studies focused on developing new algorithms or understanding complex physiological responses where a diverse dataset is crucial for long-term observational studies.
View Study Watch →Choose Zio AT ECG Monitoring System if…
Choose the Zio AT ECG Monitoring System if your primary goal is the long-term, AI-powered detection and diagnosis of cardiac arrhythmias with real-time data transmission for clinical management. This system is best suited for patients needing comprehensive ECG monitoring and detailed clinician reports to identify and manage symptomatic or asymptomatic cardiac events over an extended period, up to 14 days.
View Zio AT ECG Monitoring System →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Study Watch | Zio AT ECG Monitoring System |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | The Study Watch is a wrist-worn, multi-sensor wearable device used for data collection in clinical trials. Data from the watch is encrypted and sent securely to the Verily Cloud using a USB syncing and charging cradle and a wireless connectivity bridge (Verily Study Hub). | Cloud-based (data analytics and clinician portal) |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Zio AT ECG Monitoring SystemTool B provides a comprehensive ecosystem with a clinician portal and a patient mobile app for symptom logging and education, enhancing user interaction and management. Tool A, while having an E-ink display for simplicity, focuses more on data collection for research without explicitly detailing similar user-facing applications for patient or clinician engagement.
Clinical Value
Zio AT ECG Monitoring SystemTool B offers an FDA-cleared deep-learned AI algorithm (ZEUS System) specifically for long-term arrhythmia detection and provides comprehensive end-of-wear reports for clinicians, directly addressing a critical diagnostic need in cardiology. While Tool A also has FDA clearance and monitors physiological data for research across multiple specialties, Tool B's explicit focus on a validated AI for diagnosis provides a more direct and defined clinical value for its target application.
Pricing & Value
TieNeither tool provides publicly available pricing information, making a direct comparison of their value propositions impossible. Both require direct contact for pricing details, indicating a partnership or service-based model rather than a standardized, transparent cost structure.
Enterprise Readiness
Zio AT ECG Monitoring SystemBoth tools claim HIPAA compliance and BAA availability, and are cloud-based. However, Tool A's description explicitly mentions an ongoing lawsuit alleging BAA breaches and HIPAA violations, which, despite Verily's denials, introduces a potential risk factor for enterprise adoption that is not present in Tool B's stated facts.
Innovation
Study WatchTool A demonstrates broader innovation through its multi-modal sensor suite, collecting ECG, heart rate, electrodermal activity, and inertial movements for comprehensive physiological monitoring in clinical research. While Tool B features an FDA-cleared deep-learned AI algorithm for arrhythmia detection and extended wear time, Tool A's diverse data collection capabilities suggest a wider scope of innovative data capture for future AI applications.
Support & Docs
Zio AT ECG Monitoring SystemTool B explicitly details a 'ZioSuiteu00ae clinician portal' and 'MyZiou00ae patient mobile app' for patient management, report interpretation, symptom logging, and education, indicating a structured approach to user support and documentation. Tool A's description focuses on the device and cloud platform for research, without mentioning comparable explicit support mechanisms or user-facing documentation beyond its core functionality.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Study Watch | Zio AT ECG Monitoring System |
|---|---|---|
| Name | Study Watch | Zio AT ECG Monitoring System |
| Description | Prescription-only, sensor-based wearable for non-invasive, continuous physiological monitoring in clinical research, collecting data like ECG, heart rate, and movement for analysis in Verily's cloud platform. | FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting. |
| Company | Verily Life Sciences | iRhythm Technologies, Inc. |
| Categories | Cardiology AI, Wearables & Remote Monitoring (RPM) | Cardiology AI, Wearables & Remote Monitoring (RPM) |
| Key Features (Selected) | Continuous physiological monitoring; Multiple physiological sensors (ECG, heart rate, electrodermal activity, inertial movements); Long battery life (up to one week); Cloud-based data processing with algorithms and machine learning; On-demand single-channel ECG; Irregular pulse monitor. | Wearable Zio AT patch for continuous ECG recording; Wireless gateway for real-time data transmission; FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection; Continuous, uninterrupted ECG recording for up to 14 days; Comprehensive end-of-wear reports for clinicians; ZioSuiteu00ae clinician portal and mobile app. |
Videos
Demos, reviews, and walkthroughs featuring Study Watch and Zio AT ECG Monitoring System.
Frequently Asked Questions
More Comparisons
More matchups featuring Study Watch or Zio AT ECG Monitoring System
Backers
Who funded each tool's parent company.